EDOXABAN TOSYLATE

Search structure
Trade Names:
Synonyms:
Status: Approved (2015)
Entry Type: Small molecule
Molecule Category: Salt
UNII: 32W99UE810
Parent Compound: EDOXABAN

Structure
InChI Key ZLFZITWZOYXXAW-QXXZOGQOSA-N
Smile CN1CCc2nc(C(=O)N[C@@H]3C[C@@H](C(=O)N(C)C)CC[C@@H]3NC(=O)C(=O)Nc3ccc(Cl)cn3)sc2C1.Cc1ccc(S(=O)(=O)O)cc1
InChI
InChI=1S/C24H30ClN7O4S.C7H8O3S/c1-31(2)24(36)13-4-6-15(27-20(33)21(34)30-19-7-5-14(25)11-26-19)17(10-13)28-22(35)23-29-16-8-9-32(3)12-18(16)37-23;1-6-2-4-7(5-3-6)11(8,9)10/h5,7,11,13,15,17H,4,6,8-10,12H2,1-3H3,(H,27,33)(H,28,35)(H,26,30,34);2-5H,1H3,(H,8,9,10)/t13-,15-,17+;/m0./s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C31H38ClN7O7S2
Molecular Weight 720.27
AlogP 1.29
Hydrogen Bond Acceptor 8.0
Hydrogen Bond Donor 3.0
Number of Rotational Bond 5.0
Polar Surface Area 136.63
Molecular species NEUTRAL
Aromatic Rings 2.0
Heavy Atoms 37.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR Coagulation factor X inhibitor FDA

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Atrial Fibrillation 4 D001281 ClinicalTrials
Venous Thrombosis 4 D020246 ClinicalTrials
Venous Thromboembolism 3 D054556 ClinicalTrials
Thrombosis 2 D013927 ClinicalTrials

Related Entries

Parent

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
Vascular disorders
23.66
Nervous system disorders
11.99
Gastrointestinal disorders
9.06
Injury, poisoning and procedural complications
6.83
Respiratory, thoracic and mediastinal disorders
6.51
Cardiac disorders
6.34
General disorders and administration site conditions
5.42
Renal and urinary disorders
3.57
Investigations
3.45
Skin and subcutaneous tissue disorders
3.36
Blood and lymphatic system disorders
3.07
Musculoskeletal and connective tissue disorders
2.84
Infections and infestations
2.5

Cross References

Resources Reference
ChEBI 85975
ChEMBL CHEMBL2105682
EPA CompTox DTXSID10197399
FDA SRS 32W99UE810
PubChem 44610678
SureChEMBL SCHEMBL330918
CONTENTS